PRO DEX INC PDEX

Healthcare SIC 3841 - Surgical & Medical Instruments & Apparatus NAICS Manufacturing › Miscellaneous Manufacturing › Medical Equipment and Supplies Manufacturing › Surgical and Medical Instrument Manufacturing derived Nasdaq

"Pro-Dex," "we," "our," "us") specializes in the design, development, and manufacture

of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic,

and craniomaxillofacial ("CMF") markets. We have patented adaptive torque-limiting technology and proprietary sealing

solutions that appeal to our customers, primarily medical device distributors. Additionally, we provide engineering, quality and regulatory

Last close 62.22 2026-10-23
Market cap $199.3M 2026-06-30 share count
52-week range 28.40 - 77.00

Valuation FY2026 figures against the last close

P/S2.6x
P/E15.1x
P/FCF29.5x
EV/EBITDA14.4x
Dividend yield—
Diluted EPS4.12

Annual financial statements

Income statement

Fiscal year FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue $77.5M$66.6M$53.8M$46.1M$42.0M$38.0M$34.8M$27.2M$22.5M$21.9M
Cost of revenue $53.2M$47.1M$39.3M$33.3M$28.9M$24.5M$21.7M$17.4M$14.5M$14.8M
Gross profit $24.3M$19.5M$14.6M$12.7M$13.1M$13.6M$13.1M$9.8M$7.9M$7.2M
R&D $3.3M$3.6M$3.2M$2.8M$3.0M$4.4M$2.3M$1.9M$1.9M$1.2M
SG&A $8.0M$5.2M$4.1M$4.0M$4.9M$4.1M$3.2M$2.5M$2.3M$2.5M
Total operating expenses $11.3M$8.8M$7.4M$7.0M$8.0M$9.1M$6.1M$4.8M$5.6M$4.4M
Operating income $13.0M$10.7M$7.2M$5.8M$5.1M$4.5M$7.1M$5.0M$2.4M$2.7M
Interest expense $812.0K$829.0K$558.0K$533.0K$464.0K$352.0K$236.0K$220.0K$7.0K$12.0K
Pre-tax income $18.0M$12.1M$2.6M$9.4M$5.7M$7.6M$7.9M$5.4M$2.6M$2.8M
Income tax $4.4M$3.1M$507.0K$2.4M$1.1M$1.4M$1.8M$1.3M$989.0K$2.1M
Net income $13.7M$9.0M$2.1M$7.1M$4.6M$6.2M$6.1M$4.1M$1.6M$5.1M
EPS, basic 4.242.730.611.981.261.631.560.990.381.26
EPS, diluted 4.122.670.601.951.211.571.500.970.371.25
Shares, diluted (wtd. avg.) 3.3M3.4M3.6M3.6M3.8M3.9M4.1M4.3M4.3M4.1M

Balance sheet

Fiscal year FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents $8.2M$419.0K$2.6M$2.9M$849.0K$3.7M$6.4M$7.7M$5.2M$4.2M
Short-term investments $1.1M$6.7M$4.2M$1.1M$755.0K$1.3M$2.6M$1.7M$2.2M$718.0K
Receivables $21.2M$16.4M$13.9M$10.0M$15.4M$10.9M$5.2M$4.1M$3.0M$3.5M
Inventory $21.5M$22.2M$15.3M$16.2M$12.7M$8.4M$8.2M$6.2M$4.4M$3.1M
Total current assets $53.2M$47.3M$36.6M$31.0M$31.2M$25.0M$22.7M$20.8M$16.2M$12.3M
Property, plant and equipment $5.4M$5.2M$5.0M$5.1M$4.8M$3.8M$2.7M$2.7M$1.8M$1.4M
Goodwill $6.5M————————$112.0K
Other intangibles $686.0K$26.0K$54.0K$81.0K$118.0K$186.0K$162.0K$129.0K$140.0K$149.0K
Total assets $74.5M$61.2M$52.5M$51.8M$49.1M$42.9M$31.5M$25.5M$19.9M$16.4M
Accounts payable $4.3M$4.6M$4.5M$2.3M$3.8M$2.3M$2.0M$2.0M$1.1M$1.2M
Total current liabilities $13.0M$14.6M$12.9M$9.7M$11.4M$6.3M$5.2M$4.3M$2.4M$2.6M
Long-term debt $17.5M$15.4M$12.0M$12.8M$13.6M$12.8M$4.0M$4.6M——
Total liabilities $26.9M$24.6M$21.6M$20.2M$23.7M$20.2M$12.1M$3.3M$2.6M$2.6M
Retained earnings $47.6M$35.9M$26.9M$24.8M$17.7M$14.3M$8.1M$1.7M-$2.4M-$4.0M
Total equity $47.6M$36.6M$30.9M$31.6M$25.4M$21.1M$19.1M$17.0M$17.3M$13.7M

Cash flow

Fiscal year FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Operating cash flow $7.2M-$1.7M$6.2M$5.5M-$847.0K-$2.1M$4.9M$3.3M$3.1M$3.2M
Depreciation and amortisation $1.4M$1.2M$1.2M$857.0K$726.0K$686.0K$573.0K$438.0K$557.0K$555.0K
Stock-based compensation $688.0K$555.0K$605.0K$766.0K$1.3M$901.0K$286.0K$37.0K$194.0K$3.0K
Capital expenditure $483.0K$1.2M——$1.6M$1.8M$519.0K$1.4M$923.0K$606.0K
Investing cash flow $3.9M-$238.0K-$2.2M-$885.0K-$1.2M-$3.7M-$2.3M-$1.2M-$4.1M-$1.0M
Financing cash flow -$3.4M-$292.0K-$4.3M-$2.5M-$790.0K$3.1M-$4.0M$450.0K$2.0M-$298.0K
Buybacks $3.4M$3.5M$3.5M$1.5M$1.6M$5.5M$3.4M$4.0M$220.0K$312.0K

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001079973-26-001215.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. 0 20M 40M 60M 80M Revenue, FY2017: 21.9M Gross profit, FY2017: 7.2M Net income, FY2017: 5.1M Revenue, FY2018: 22.5M Gross profit, FY2018: 7.9M Net income, FY2018: 1.6M Revenue, FY2019: 27.2M Gross profit, FY2019: 9.8M Net income, FY2019: 4.1M Revenue, FY2020: 34.8M Gross profit, FY2020: 13.1M Net income, FY2020: 6.1M Revenue, FY2021: 38M Gross profit, FY2021: 13.6M Net income, FY2021: 6.2M Revenue, FY2022: 42M Gross profit, FY2022: 13.1M Net income, FY2022: 4.6M Revenue, FY2023: 46.1M Gross profit, FY2023: 12.7M Net income, FY2023: 7.1M Revenue, FY2024: 53.8M Gross profit, FY2024: 14.6M Net income, FY2024: 2.1M Revenue, FY2025: 66.6M Gross profit, FY2025: 19.5M Net income, FY2025: 9M Revenue, FY2026: 77.5M Gross profit, FY2026: 24.3M Net income, FY2026: 13.7M FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025 FY2026
Fiscal year FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Revenue $21.9M $22.5M $27.2M $34.8M $38.0M $42.0M $46.1M $53.8M $66.6M $77.5M
Gross profit $7.2M $7.9M $9.8M $13.1M $13.6M $13.1M $12.7M $14.6M $19.5M $24.3M
Net income $5.1M $1.6M $4.1M $6.1M $6.2M $4.6M $7.1M $2.1M $9.0M $13.7M

Recent filings and events

  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Acquisition or disposal completed A purchase or sale of a significant business or asset has closed. Item 2.01
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Regulation FD disclosure Item 7.01
  • Results announced Item 2.02
  • Officer or director change Item 5.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 3841

TickerCompanyMarket capP/ERevenue growth
SYK STRYKER CORP $117.81B 36.6x 11.2%
MMM 3M CO $89.46B 28.9x 1.5%
BSX BOSTON SCIENTIFIC CORP $66.22B 23.6x 19.9%
BDX BECTON DICKINSON & CO $54.18B 34.2x 8.2%
RMD RESMED INC $36.48B 24.2x 9.9%
DXCM DEXCOM INC $29.41B 37.3x 15.6%
MDLN Medline Inc. $29.20B — 11.5%
WST WEST PHARMACEUTICAL SERVICES INC $27.60B 57.8x 6.3%